EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma
Condition(s):Ovarian Carcinosarcoma; Uterine CarcinosarcomaLast Updated:February 8, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Ovarian Carcinosarcoma; Uterine CarcinosarcomaLast Updated:February 8, 2024Recruiting
Condition(s):Metastatic Cervical CancerLast Updated:June 29, 2023Withdrawn
Condition(s):Ovarian Cancer; CarcinosarcomaLast Updated:August 10, 2021Withdrawn
Condition(s):Gynaecological CancerLast Updated:March 30, 2023Recruiting
Condition(s):Vulvar CancerLast Updated:August 14, 2023Not yet recruiting
Condition(s):Ovarian CancerLast Updated:December 23, 2015Withdrawn
Condition(s):Ovarian Cancer; Fallopian Tube CancerLast Updated:March 29, 2018Unknown status
Condition(s):Recurrent Platinum-sensitive Ovarian CancerLast Updated:July 13, 2021Completed
Condition(s):Endometrial CancerLast Updated:October 11, 2023Active, not recruiting
Condition(s):Ovarian CancerLast Updated:September 23, 2015Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.